Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, September 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2025 (2025-09-30): -421.09%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
86.70%
RETURN ON EQUITY (ROE) AVG 3Y
6.56%
RETURN ON EQUITY (ROE) AVG 5Y
-211.25%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inhibrx Biosciences Inc.
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
86.70%
3Y Avg
6.56%
5Y Avg
-211.25%
Market Cap
$1.41B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.42B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.43B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.43B
Return on Equity (ROE)
N/A
TTM Avg
247.90%
3Y Avg
18.71%
5Y Avg
1.58%
Market Cap
$1.45B
Return on Equity (ROE)
-29.48%
TTM Avg
-5.20%
3Y Avg
-280.62%
5Y Avg
-280.62%
Market Cap
$1.35B
Return on Equity (ROE)
N/A
TTM Avg
44.32%
3Y Avg
153.88%
5Y Avg
43.56%
Market Cap
$1.35B
Return on Equity (ROE)
N/A
TTM Avg
36.18%
3Y Avg
36.18%
5Y Avg
36.18%
Market Cap
$1.45B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | N/A | 86.70% | 6.56% | -211.25% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | 41.79% | 41.79% | 41.79% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 9.00% | 8.29% | 7.90% | 8.39% |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | 247.90% | 18.71% | 1.58% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | -29.48% | -5.20% | -280.62% | -280.62% |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 44.32% | 153.88% | 43.56% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | 36.18% | 36.18% | 36.18% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | -7.08% | -0.64% | -1.30% | -2.08% |
ROE
N/A
ROA
-89.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -421.09% |
| 2025-06-30 | -238.76% |
| 2024-09-30 | 919.96% |
| 2024-06-30 | 744.83% |
| 2023-12-31 | -554.30% |
| 2023-09-30 | -145.41% |
| 2022-12-31 | -259.31% |
| 2022-03-31 | -342.72% |
| 2021-12-31 | -156.10% |
| 2021-09-30 | -277.40% |
| 2021-06-30 | -176.32% |
| 2021-03-31 | -124.30% |
| 2020-12-31 | -100.86% |
| 2020-09-30 | -81.52% |
